CROI (Conference on Retroviruses and Opportunistic Infections)
The Latest
'Drug Users Are People Too': Addressing Opioid Addiction, Chemsex, Alcoholism, and Smoking Among People Living With HIV
A CROI 2019 symposium demonstrated the need for continued research and programs that address substance use and its impact on people living with HIV.
People With HIV Have Substantially Higher Risk of Sudden Cardiac Death at Low CD4 Counts or Detectable Viral Load
New research involving veterans highlights the need to monitor HIV-positive patients for cardiovascular risk.
Drug Use May Be Increasing Syphilis Rates Among HIV-Positive Cisgender Women, Studies Show
The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.
CROI 2019: What News to Expect in HIV Science and Policy
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
Reducing Risk of Myocardial Infarction in HIV-Positive People
This year at CROI 2018 a few studies tried to explore possible mechanisms for the association of increased myocardial infarction risk and abacavir use.
HIV/HCV Coinfection: New Data Has Implications for Treatment-as-Prevention Efforts
Researchers at this year's Conference on Retroviruses and Opportunistic Infections (CROI) presented their findings on the ongoing challenges of treating hepatitis C infection among people with HIV.
Rate of Bone Loss on ART Slows After the First Year
Reassuring data that the initial loss in bone mineral density during the first year of antiretroviral therapy slowed during subsequent years.
Statin Use Might Reduce Risk of Cancer in HIV-Positive People
A large case-control analysis reported an overall association between statin use and a reduced risk of virus-mediated cancers in HIV-positive people.
Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment
New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.
Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.